Vanguard Personalized Indexing Management LLC Raises Position in Editas Medicine, Inc. $EDIT

Vanguard Personalized Indexing Management LLC raised its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 55.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,366 shares of the company’s stock after acquiring an additional 14,765 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Editas Medicine were worth $91,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its holdings in Editas Medicine by 13.5% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 51,105 shares of the company’s stock valued at $112,000 after purchasing an additional 6,088 shares in the last quarter. Acadian Asset Management LLC raised its position in shares of Editas Medicine by 288.5% in the first quarter. Acadian Asset Management LLC now owns 752,162 shares of the company’s stock valued at $869,000 after buying an additional 558,567 shares during the last quarter. SCS Capital Management LLC purchased a new position in shares of Editas Medicine in the first quarter worth about $41,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Editas Medicine by 122.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,600,000 shares of the company’s stock worth $3,016,000 after acquiring an additional 1,430,000 shares during the last quarter. Finally, State of Wyoming acquired a new position in Editas Medicine during the first quarter worth about $51,000. Hedge funds and other institutional investors own 71.90% of the company’s stock.

Editas Medicine Trading Up 1.9%

Shares of NASDAQ EDIT opened at $3.72 on Monday. The stock has a market capitalization of $334.50 million, a PE ratio of -1.31 and a beta of 2.18. Editas Medicine, Inc. has a twelve month low of $0.91 and a twelve month high of $4.54. The stock has a fifty day simple moving average of $3.18 and a 200-day simple moving average of $2.47.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Tuesday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.22). Editas Medicine had a negative return on equity of 200.25% and a negative net margin of 608.88%.The business had revenue of $3.58 million for the quarter, compared to analyst estimates of $1.81 million. On average, equities analysts predict that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on EDIT shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research note on Friday. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. Wells Fargo & Company upped their target price on Editas Medicine from $3.00 to $4.00 and gave the company an “equal weight” rating in a report on Wednesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Editas Medicine in a research note on Friday, September 5th. Finally, Robert W. Baird lifted their price target on Editas Medicine from $4.00 to $6.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, Editas Medicine has an average rating of “Hold” and a consensus price target of $5.10.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.